Protein C Zymogen in Severe Sepsis: a Double-blinded, Placebo-controlled, Randomized Study

Overview

Journal Intensive Care Med

Specialty Critical Care

Date 2016 Jun 27

PMID 27344436

Citations 7

Authors

Federico Pappalardo

Martina Crivellari

Ambra L Di Prima

Nataliya Agracheva

Malgorzata Celinska-Spodar

Rosalba Lembo

Daiana Taddeo

Giovanni Landoni

Alberto Zangrillo

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine whether protein C zymogen (protein C concentrates or human protein C) improves clinically relevant outcomes in adult patients with severe sepsis and septic shock.

Methods: This is a randomized, double-blind, placebo-controlled, parallel-group trial that from September 2012 to June 2014 enrolled adult patients with severe sepsis or septic shock and high risk of death and of bleeding (e.g., APACHE II greater than 25, extracorporeal membrane oxygenation or disseminated intravascular coagulopathy). All patients completed their follow-up 90 days after randomization and data were analyzed according to the intention-to-treat principle. Follow-up was performed at 30 and 90 days after randomization. The primary endpoint was a composite outcome of prolonged intensive care unit (ICU) stay and/or 30-day mortality. Secondary endpoints included mortality.

Results: The study was stopped early in a situation of futility for the composite outcome of prolonged ICU stay and/or 30-day mortality that was 79 % (15 patients) in the protein C zymogen group and 67 % (12 patients) in the placebo group (p = 0.40) and for a concomitant safety issue: ICU mortality was 79 % (15 patients) in the protein C zymogen group vs 39 % (7 patients) in the placebo group (p = 0.020), and 30-day mortality was 68 vs 39 % (p = 0.072).

Conclusion: Protein C zymogen did not improve clinically relevant outcomes in severe sepsis and septic shock adult patients. Given its high cost and the potential increase in mortality, the use of this drug in adult patients should be discouraged.

Citing Articles

The transition of the criteria for disseminated intravascular coagulation and the targeted patients in randomized controlled trials over the decades: a scoping review.

Matsuoka T, Yamakawa K, Umemura Y, Homma K, Iba T, Sasaki J Thromb J. 2024; 22(1):112.

PMID: 39716150 PMC: 11665092. DOI: 10.1186/s12959-024-00681-w.

Endothelial dysfunction and immunothrombosis in sepsis.

Maneta E, Aivalioti E, Tual-Chalot S, Emini Veseli B, Gatsiou A, Stamatelopoulos K Front Immunol. 2023; 14:1144229.

PMID: 37081895 PMC: 10110956. DOI: 10.3389/fimmu.2023.1144229.

A Pathophysiological Perspective on the SARS-CoV-2 Coagulopathy.

Kusadasi N, Sikma M, Huisman A, Westerink J, Maas C, Schutgens R Hemasphere. 2020; 4(4):e457.

PMID: 32885147 PMC: 7430228. DOI: 10.1097/HS9.0000000000000457.

ICM focus on thrombosis and bleeding.

Moller M, Skrifvars M, Azoulay E Intensive Care Med. 2017; 43(12):1910-1911.

PMID: 29063131 DOI: 10.1007/s00134-017-4966-y.

Is protein C zymogen really ineffective for ALL cases of sepsis including septic DIC?.

Iba T, Thachil J Intensive Care Med. 2016; 43(1):152-153.

PMID: 27822595 DOI: 10.1007/s00134-016-4615-x.

References

Brun-Buisson C, Meshaka P, Pinton P, Vallet B . EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med. 2004; 30(4):580-8. DOI: 10.1007/s00134-003-2121-4. View

Guidet B, Beale R . Should cost considerations be included in medical decisions? Yes. Intensive Care Med. 2015; 41(10):1838-40. DOI: 10.1007/s00134-015-3988-6. View

Baratto F, Michielan F, Meroni M, Dal Palu A, Boscolo A, Ori C . Protein C concentrate to restore physiological values in adult septic patients. Intensive Care Med. 2008; 34(9):1707-12. DOI: 10.1007/s00134-008-1140-6. View

Crivellari M, Della Valle P, Landoni G, Pappalardo F, Gerli C, Bignami E . Human protein C zymogen concentrate in patients with severe sepsis and multiple organ failure after adult cardiac surgery. Intensive Care Med. 2009; 35(11):1959-63. DOI: 10.1007/s00134-009-1584-3. View

Taylor Jr F, Toh C, Hoots W, Wada H, Levi M . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2002; 86(5):1327-30. View

Decembrino L, DAngelo A, Manzato F, Solinas A, Tumminelli F, De Silvestri A . Protein C concentrate as adjuvant treatment in neonates with sepsis-induced coagulopathy: a pilot study. Shock. 2010; 34(4):341-5. DOI: 10.1097/SHK.0b013e3181e7623e. View

De Leonardis F, Koronica R, Bruno S, Santoro N . Non-activated protein C rescue treatment in Wilms tumour associated hepatic sinusoidal obstructive syndrome. Pediatr Blood Cancer. 2013; 61(5):940-1. DOI: 10.1002/pbc.24859. View

Dellinger R, Levy M, Rhodes A, Annane D, Gerlach H, Opal S . Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013; 39(2):165-228. PMC: 7095153. DOI: 10.1007/s00134-012-2769-8. View

Rintala E, Kauppila M, Seppala O, Voipio-Pulkki L, Pettila V, Rasi V . Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med. 2000; 28(7):2373-8. DOI: 10.1097/00003246-200007000-00032. View

10.

. ICH harmonised tripartite guideline: guideline for good clinical practice. 8. Essential documents for the conduct of a clinical trial. J Postgrad Med. 2002; 47(4):264-7. View

11.

Gaieski D, Edwards J, Kallan M, Carr B . Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013; 41(5):1167-74. DOI: 10.1097/CCM.0b013e31827c09f8. View

12.

Esmon C . The interactions between inflammation and coagulation. Br J Haematol. 2005; 131(4):417-30. DOI: 10.1111/j.1365-2141.2005.05753.x. View

13.

Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S . Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013; 310(16):1683-91. DOI: 10.1001/jama.2013.278477. View

14.

Ranieri V, Thompson B, Barie P, Dhainaut J, Douglas I, Finfer S . Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012; 366(22):2055-64. DOI: 10.1056/NEJMoa1202290. View

15.

Yeo H, Kim D, Jeon D, Kim Y, Cho W . Low-dose heparin during extracorporeal membrane oxygenation treatment in adults. Intensive Care Med. 2015; 41(11):2020-1. DOI: 10.1007/s00134-015-4015-7. View

16.

Salvo I, Landoni G, Mucchetti M, Cabrini L, Pani L . Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience. Paediatr Anaesth. 2014; 24(6):625-31. DOI: 10.1111/pan.12403. View

17.

Crivellari M, Silvetti S, Gerli C, Landoni G, Franco A, Bove T . Protein C zymogen in adults with severe sepsis or septic shock. Med Intensiva. 2013; 38(5):278-82. DOI: 10.1016/j.medin.2013.04.005. View

18.

Zhao H, Heard S, Mullen M, Crawford S, Goldberg R, Frendl G . An evaluation of the diagnostic accuracy of the 1991 American College of Chest Physicians/Society of Critical Care Medicine and the 2001 Society of Critical Care Medicine/European Society of Intensive Care Medicine/American College of Chest.... Crit Care Med. 2012; 40(6):1700-6. DOI: 10.1097/CCM.0b013e318246b83a. View

19.

Bruley D, Jagannath S, Streiff M . Zymogen Protein C to prevent clotting without bleeding during invasive medical procedures. Adv Exp Med Biol. 2011; 701:91-7. DOI: 10.1007/978-1-4419-7756-4_13. View

20.

Bernard G, Vincent J, Laterre P, LaRosa S, Dhainaut J, Lopez-Rodriguez A . Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344(10):699-709. DOI: 10.1056/NEJM200103083441001. View